Comparison

Dihydroartemisinin

Item no. CS-5595-100mg
Manufacturer ChemScene
Amount 100mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 71939-50-9
Available
Alternative Names
Dihydroqinghaosu; beta-Dihydroartemisinin; Artenimol
CAS
71939-50-9
Purity
>98%
Formula
C15H24O5
MWt
284.35
Solubility
DMSO : 41.67 mg/mL (146.54 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Autophagy; Anti-infection; NF-kappaB
Target
Autophagy; Parasite; NF-kappaB
Biological Activity
Dihydroartemisinin is a potent anti-malaria agent. IC50 & Target: RelA/p65[1]
Autophagy[1] In Vitro: Dihydroartemisinin (DHA) is an antimalarial agent. Dihydroartemisinin treatment effectively up-regulates the cytosolic RelA/p65 protein level and down-regulates the nuclear RelA/p65 protein level. Dihydroartemisinin blocks the nuclear translocation of RelA/p65 from the cytosol rather than suppressing RelA/p65 protein synthesis. Dihydroartemisinin induces autophagy in RPMI 8226 cells. Dihydroartemisinin suppresses NF-kappaB activation in RPMI 8226 cells. The NF-kappaB Dihydroartemisinin -binding activity is examined by EMSA assay. RPMI 8226 cells are exposed to various concentrations of Dihydroartemisinin (10, 20 and 40 uM) for 12 h, and TNF-alpha is introduced as a positive control for NF-kappaB activation. Dihydroartemisinin suppresses NF-kappaB activation in a dose-dependent manner in contrast with TNF-alpha[1]. Dihydroartemisinin (DHA) can enhance the anti-tumor effect of photodynamic therapy (PDT) on esophageal cancer cells, and cell viability is investigated using the MTT assay. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 uM), PDT (25 and 20 J/cm2, respectively) or their combination. Single treatment with Dihydroartemisinin or PDT causes a 37+/-5% or 34+/-6% reduction in viability in Eca109 cells and a 33+/-7% or 34+/-6% reduction in Ec9706 cells, respectively. However, when PDT is combined with Dihydroartemisinin, the cell viability is reduced 59+/-6% or 61+/-7% in the cell lines, respectively[2]. In Vivo: Single oral doses of Dihydroartemisinin (at 200, 300, 400 or 600 mg/kg), given once on each of day 6-8 post-infection, reduce total-worm burdens by 69.2%-90.6% and female-worm burdens by 62.2%-92.2%, depending on dosage in the first experiment. Similar treatments given on day 34-36 post-infection reduce total-worm burdens by 73.9%-85.5% and female-worm burdens by 83.8%-95.3%[3].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close